Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Sponsor: Collegium Medicum w Bydgoszczy
Summary
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion. The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available. The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.
Official title: FLOzins for pREveNtion of Contrast-inducEd Acute Kidney Injury (FLORENCE) Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
4000
Start Date
2025-11-01
Completion Date
2026-03-31
Last Updated
2025-11-17
Healthy Volunteers
No
Conditions
Interventions
Flozin
Patients who underwent percutaneous coronary interventions while using empagliflozin or dapagliflozin
Locations (1)
Collegium Medicum w Bydgoszczy
Bydgoszcz, Poland